| Robert M Williams Md Pc | |
|
100 Kingston Ave Barrington NJ 08007-1118 | |
| (856) 547-1177 | |
| (856) 547-2509 |
| Full Name | Robert M Williams Md Pc |
|---|---|
| Speciality | Family Medicine |
| Location | 100 Kingston Ave, Barrington, New Jersey |
| Authorized Official Name and Position | Susan Jane Williams (OFFICE MANAGER) |
| Authorized Official Contact | 8565471177 |
| Accepts Medicare Insurance | This clinic does not participate in Medicare Program. |
| Mailing Address | Practice Location Address |
|---|---|
| Robert M Williams Md Pc 100 Kingston Ave Barrington NJ 08007-1118 Ph: (856) 547-1177 | Robert M Williams Md Pc 100 Kingston Ave Barrington NJ 08007-1118 Ph: (856) 547-1177 |
| NPI Number | 1548440951 |
|---|---|
| Provider Enumeration Date | 11/14/2007 |
| Last Update Date | 11/14/2007 |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1548440951 | NPI | - | NPPES |
| 10459 | Other | NJ | AETNA |
| 2269011001 | Other | NJ | AMERIHEALTH |
| P00015887 | Other | NJ | RAILROAD MEDICARE |
| 0086142000 | Other | NJ | KEYSTONE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 25MA039291 (New Jersey) | Primary |
News Archive
Outbreaks of meningitis can quickly reach epidemic proportions across a number of African countries, afflicting tens of thousands of people. Now a new vaccine appears capable of completely eradicating the disease.
CureVac AG, a fully-integrated biotechnology company pioneering mRNA-based drugs, today announced it has initiated a Phase I study assessing the intratumoral application of its novel RNAdjuvant technology in patients with superficial solid tumors that are easily accessible for repeated intratumoral injections. RNAdjuvant is designed to amplify the scope and quality of an immune response when used alone or in combination with other immune therapies.
MedImmune has received confirmation from the U.S. Food & Drug Administration (FDA) that the Agency has filed the Company's supplemental Biologics License Application (sBLA) for a quadrivalent (four-strain) version of FluMist® (Influenza Vaccine Live, Intranasal). The company submitted the sBLA early in the second quarter of this year.
OptMed Inc., a medical device manufacturer, announced today that the Company received 510(k) marketing clearance from the US Food and Drug Administration for its BondEase product, a topical skin adhesive intended for the closure of surgical incisions and lacerations as an alternative to sutures and staples.
Late adolescence is a period when many youth become involved in high-risk behaviors with adverse consequences. Researchers at the Mailman School of Public Health with colleagues at Johns Hopkins University studied the degree to which two such behaviors, adolescent sexual behaviors and gambling, affected African American youth in nine primary schools in Baltimore, MD.
› Verified 9 days ago